[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637413":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":48,"collaborators":52,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":11,"enrollmentInfo":67,"targetDuration":11,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Rigshospitalet, Denmark","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cancer patients","EXPERIMENTAL",null,[13],"Drug: [68Ga]Ga-FAPI-46",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","[68Ga]Ga-FAPI-46","PET\u002FCT scan with the tracer \\[68Ga\\]Ga-FAPI-46",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Marie M K Stolberg, MD","CONTACT","+4535454416","marie.manon.krebs.krarup@regionh.dk",[27],{"facility":28,"status":29,"city":30,"state":11,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Rigshospitalet","RECRUITING","Copenhagen","2100","Denmark","DK",{"type":35,"coordinates":36},"Point",[37,38],12.56553,55.67594,{"lat":38,"lon":37},[41,44,46],{"name":22,"role":23,"phone":42,"phoneExt":43,"email":25},"+45 35454416","+45 35453545",{"name":45,"role":23,"phone":11,"phoneExt":11,"email":11},"Barbara M Fischer, professor, Professor, MD, Ph.D.",{"name":22,"role":47,"phone":11,"phoneExt":11,"email":11},"SUB_INVESTIGATOR",{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Barbara Malene Fischer","Professor, MD, Ph.D.",[53,55],{"name":54,"class":6},"Danish Cancer Society",{"name":56,"class":6},"Herlev Hospital","100637413","phase-2-befast-study-68gaga-fapi-total-body-petct-for-better-and-faster-imaging-in-cancer-100637413",false,"NCT07629609","BEFAST Study, [68Ga]Ga-FAPI Total Body PET\u002FCT for Better and Faster Imaging in Cancer","[68Ga]Ga-FAPI Total Body PET\u002FCT for Improving Diagnostic Sensitivity and Preoperative Staging in Gastroesophageal Cancer and Pancreatic Cancer","BEFAST","Inclusion criteria for group A\n\n1. Male or female, over 18 years old\n2. Patients with suspected pancreatic cancer based on morphological findings on standard imaging\n3. CT or MRI or \\[18F\\]FDG PET\u002FCT evaluated on MDT with no initial sign of distant metastases\n4. Subjects must have been considered suitable for curative surgery at the time of the referral\n5. Subjects must be able to read and understand the patient information in Danish to give informed consent\n\nInclusion criteria for group B1\n\n1. Male or female over 18 years old\n2. Histological verified carcinoma from the lower esophagus, GEJ, or stomach\n3. Subjects must be considered operable and resectable at the time of referral for MDT\n4. Subjects must be able to read and understand the patient information in Danish to give informed consent\n\nInclusion criteria for group B2\n\n1. Male or female over 18 years old\n2. Histological verified SRCC or PCC from the lower esophagus, GEJ, or stomach\n3. Subjects with localized disease assigned to perioperative chemotherapy or subjects with metastatic disease assigned to palliative systemic treatment.\n4. Subjects must be able to read and understand the patient information in Danish to give informed consent\n\nExclusion Criteria:\n\n1. Pregnancy or lactation\n2. Weight more than the maximum limit of a PET\u002FCT-scanner bed (140 kg)\n3. History of allergic reaction due to compounds similar to the chemical composition of \\[68Ga\\]Ga-FAPI-46","ALL","18 Years",{"count":68,"type":69},90,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","The goal of this clinical trial is to learn if \\[68Ga\\]Ga-FAPI-46 Total Body PET\u002FCT can diagnose patients suffering from gastroesophageal cancer and pancreatic cancer. The investigators hope that \\[68Ga\\]Ga-FAPI-46 Total Body PET\u002FCT can improve staging and treatment evaluation for these patient groups.\n\nThe main questions the trial aims to answer are:\n\n* Is \\[68Ga\\]Ga-FAPI-46 Total Body PET\u002FCT better at diagnosing metastatic disease in the abdomen compared other imaging modalities?\n* Can \\[68Ga\\]Ga-FAPI-46 Total Body PET\u002FCT produce accurate images in less than 30 min?\n\nResearchers will examine three different patient groups:\n\nGroup A) patients with pancreatic cancer, who are referred to surgery. Group B1) patients with gastroesophageal cancer, who are referred to diagnostic surgery (laparoscopy).\n\nGroup B2) a subgroup of gastroesophageal cancer patients, with a specific subtype cancer (signet ring cell carcinoma or poorly cohesive carcinoma), who are referred to oncological treatment.\n\nParticipants will undergo:\n\n* One \\[68Ga\\]Ga-FAPI Total Body PET\u002FCT before surgery (Group A), or before laparoscopy (group B1), or before oncological treatment (Group B2).\n* Participants in group B2 will also undergo a second \\[68Ga\\]Ga-FAPI-46 Total Body PET\u002FCT during treatment with chemotherapy.\n* All participants will fill out one questionnaire.\n* Researchers will follow the patients after the scans for 1 year.",[75,76],"Pancreatic Cancer, Adult","Gastroesophageal Cancer (GC)",[78,79,80,81,82],"PET\u002FCT","FAPI","pancreatic cancer","gastroesophageal cancer","signet ring cell carcinoma","2026-06-01",{"date":85,"type":86},"2026-06-05","ACTUAL",{"date":88,"type":86},"2024-01-16",{"date":90,"type":69},"2027-01",{"name":50,"class":6},1]